




RealRate

MEDICINAL PRODUCTS 2023

Navidea Biopharmaceuticals Inc. Rank 46 of 48





RealRate

MEDICINAL PRODUCTS 2023

Navidea Biopharmaceuticals Inc. Rank 46 of 48



The relative strengths and weaknesses of Navidea Biopharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Navidea Biopharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 53% points. The greatest weakness of Navidea Biopharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 134% points.

The company's Economic Capital Ratio, given in the ranking table, is -262%, being 257% points below the market average of -5.0%.

Input Variable	Value in 1000 USD
Assets, Current	3,204
Assets, Non-Current	32
General and Administrative Expense	7,964
Goodwill	1,000
Liabilities, Current	9,942
Liabilities, Non-Current	1.3
Other Assets	0
Other Compr. Net Income	0
Other Expenses	183
Other Liabilities	2,572
Other Net Income	-1,126
Other Revenues	66
Property, Plant and Equipment, Net	135
Research and Development	5,970

Output Variable	Value in 1000 USD
Liabilities	12,515
Assets	4,372
Expenses	14,117
Revenues	66
Stockholders Equity	-8,143
Net Income	-15,177
Comprehensive Net Income	-15,177
Economic Capital Ratio	-262%